Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Open
-
An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of cevostamab (BFCR4350A) in Patients With Relapsed or Refractory Multiple Myeloma
Scottsdale/Phoenix, Ariz.
This is a phase I, multicenter, open-label, dose-escalation study of cevostamab (BFCR4350A) administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
-
C1071009: MAGNETISMM-9, A Phase 1/2, Open-label, Multicenter Study to Evaluate a Dosing Regimen with Two Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (PF-06863135) Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma (MagnetisMM-9)
Scottsdale/Phoenix, Ariz.
The purpose of this study is to evaluate the safety of a step-up dosing approach (starting with low doses followed by higher doses) of the study medicine (elranatamab) in participants with multiple myeloma that has come back after responding to treatment or has not responded to treatment (relapsed/refractory multiple myeloma). This study will also look at the safety and effectiveness of different doses of elranatamab, as well as different intervals between doses. Participants in the study will receive elranatamab as an injection under the skin at the study clinic. After the initial step-up doses, participants will start receiving one dose every week. The frequency of clinic visits for injections may then decrease over time. Participation will be at least two years.
-
MC210809, Evaluating Mechanisms of Immunomodulator Sensitivity and Resistance in Multiple Myeloma (MC210809)
Rochester, Minn.,
Jacksonville, Fla.,
Scottsdale/Phoenix, Ariz.
The primary goal of this study is to determine response rates (>=PR) of prospectively treated MM patients with one cycle of therapy containing a combination of an immunomodulator and dexamethasone.
Closed for Enrollment
-
Phase II Trial of Nab-paclitaxel (Abraxane®) in Patients With Relapsed or Refractory Multiple Myeloma
Scottsdale/Phoenix, Ariz.
This phase II trial studies how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with multiple myeloma that has returned or did not respond to treatment. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
.